ClinicalTrials.gg
RecruitingNCT07029009Updated Dec 17, 2025

Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)

A Phase 2 interventional study of Liraglutide in Maturity Onset Diabetes of the Young, sponsored by Mansa. Recruiting at 1 site in United States. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Mansa · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Planned enrollment
85th of 151
50 · median 62
Started
2025
with 1 other
Phase 2
18 of 151
2 open now
Registered
150th of 151
by date

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 85th largest by planned enrollment, is one of 2 that started in 2025, is one of 18 in phase 2, and was the 150th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 10 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY).

The investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastrointestinal (GI) issues such as an upset stomach. Investigators also are interested in finding out if this drug will help with GI issues.

If liraglutide does help with this symptom of MODY, the investigators want to know why this happens. If this drug is effective for participants, the investigators will use participants cells to make human induced pluripotent stem cell (iPSC). This means that the investigators will use participant cells to create what are called stem cells, which are cells in the body that are able to be told what their job is. Investigators will use these cells to see what happens in gastrointestinal (GI) tract.

Read the detailed description

The objective of this study is to perform a comprehensive metabolic and hormonal evaluation of individuals with Maturity-onset diabetes of the young (MODY) at baseline and then assess response to initiation of liraglutide. Select individuals will be consented for human induced pluripotent stem cell (iPSC) generation to identify the cellular basis of enteroendocrine cell (EEC) dysfunction.

The hypothesis is that heterozygous mutations in MODY-related genes contribute to a range of GI pathologies, including regional disruptions in epithelial identity and disturbances in the function of EECs. Thus, patients with MODY may experience improvement not only in HbA1c and BMI but also in GI symptoms with initiation of GLP-1 receptor agonists. Investigators plan to enroll approximately 50 patients with MODY and obtain baseline metabolic labs and imaging along with enteroendocrine labs before initiating liraglutide and assessing response with repeat labs and imaging. This project will provide further guidance for clinical care and treatment of patients with MODY.

03

Conditions studied

  • Maturity Onset Diabetes of the Young
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MODY via genetic testing
  • HgbA1c >6.5%

Exclusion criteria

Exclusion Criteria:

  • History of anaphylaxis to GLP-1 receptor agonists
  • Already taking GLP-1 receptor agonists
  • on medications within the stimulant class
  • have had bariatric surgery
  • personal or family history of cancer, especially medullary thyroid cancer
  • personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis
  • known active kidney disease
  • severe hypoglycemia (glucose \< 50 mg/dL) within 3 months of study enrollment
  • > 10.0%
  • episode of diabetic ketoacidosis (DKA) in the past 3 months
  • are currently pregnant
  • \< 18.5 kg/m2 and pediatric patients with BMI \< 5th percentile
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    liraglutide treatment

    After baseline evaluation of enteroendocrine levels and metabolism, study participants will be prescribed liraglutide. Titration of liraglutide will be as follows: 1) Starting dose of liraglutide 0.6 mg daily for 1 week, 2) Increase to liraglutide 1.2 mg daily for 1 week, and 3) Maintain at final dose of liraglutide 1.8 mg daily. If study participants are unable to tolerate liragultide 1.8 mg daily due to side effects for 1 week, then will decrease back to liraglutide 1.2 mg daily.

    Drug: Liraglutide

Interventions

  • Liraglutide will be prescribed following FDA approved packet insert for type 2 diabetes in our test population.

    Also known as: Victoza, Saxenda

06

What researchers measure

Primary outcomes

  1. Blood sugar control - HbA1C

    Hemoglobin A1c

    Time frame: Baseline and 3 months after study treatment initiation

  2. BMI

    Body mass index; weight and height will be combined to report BMI in kg/m\^2

    Time frame: baseline, 1 month, 2 months, and final study visit 3 months after study treatment initiation

Secondary outcomes

  1. Metabolic - Blood Sugar

    Glycemic patterns observed utilizing a continuous glucose monitor

    Time frame: Baseline through three months of study treatment

  2. Enteroendocrine function - GI symptoms

    ANMS Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD)

    Time frame: baseline, 1 month, 2 months, and final study visit 3 months after study treatment initiation

  3. Enteroendocrine function - insulin

    Fasting and post meal blood serum insulin levels will be assessed

    Time frame: baseline and 3 months after study treatment initiation

  4. Enteroendocrine function - c-peptide

    Fasting and post meal blood serum c-peptide levels will be assessed

    Time frame: baseline and 3 months after study treatment initiation

  5. Body fat percentage

    % body fat as identified by DXA

    Time frame: baseline, 1 month, 2 months, and final study visit 3 months after study treatment initiation

  6. Liver steatosis

    MRI to determine liver health

    Time frame: baseline and 3 months after treatment initiation

07

Study locations

1 of 1 sites recruiting
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
    Recruiting
    • Lily Deng · Contactlily.deng@cchmc.org · 513-636-0002
    • Mansa Krishnamurthy · Principal investigator
    • Lily Deng · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — individual participant data will not be made available to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Aug 2026, 15 months after the start.

Of 99 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 15 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Jun 19, 2025
StartActual
May 8, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Jan 2027
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07029009
Lead sponsor
Mansa
Responsible party
Mansa (ASSISTANT PROFESSOR, Children's Hospital Medical Center, Cincinnati) — Sponsor-investigator
First posted
Jun 19, 2025
Start date
May 8, 2025
Primary completion
Aug 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Dec 17, 2025

Study contacts

Mansa Krishnamurthy, M.D.
Contact
mansa.krishnamurthy@cchmc.org
513-636-4744
Mansa Krishnamurthy, M.D.
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion